Novel biomarkers to improve prostate cancer predictions: The research continues

Poster Session 08

Friday 15 March
10:45 - 12:15

Location: Green Area, Room 5

Chairs: G. Giannarini, Udine (IT)
J.A. Schalken, Nijmegen (NL)
G. Zhu, Beijing (CN)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

100 Use of the PHI assay as a first line triaging test in an image-guided prostate cancer diagnostic pathway. The PHI in Refining MRI (PRIM) study

By: Gnanapragasam V.J., Barret T., Starling L., George A., Burling K., Saeb-Parsy K., Kastner C., Lamb B., Kim L.

1 University of Cambridge, Academic Urology Group, Cambridge, United Kingdom,
2 University of Cambridge, Dept. of Radiology, Cambridge, United Kingdom,
3 University of Cambridge, Dept. of Urology Translational Research and Clinical Trials, Cambridge, United Kingdom,
4 University of Cambridge, Dept. of Core Biochemistry and Analytical Laboratory, Cambridge, United Kingdom,
5 Cambridge University Hospitals Trust, Dept. of Urology, Cambridge, United Kingdom,
6 University of Cambridge, Dept. of Public Health and Primary Care, Cambridge, United Kingdom

101 External validation of SelectMDx (v1) in an opportunistic screening cohort in first TRUS-guided biopsy without MRI imaging


1 Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain,
2 Hospital Miguel Servet, Dept. of Urology, Zaragoza, Spain,
3 Escuela Universitaria Politécnica La Almunia, Universidad de Zaragoza, Dept. of Biostatistics, Zaragoza, Spain,
4 Instituto Valenciano de Oncología, Dept. of Statistics, Valencia, Spain

102 Percent genome alteration predicts adverse oncologic outcomes after radical prostatectomy in African American men: A profile of cancer genomics by racial ancestry

By: Faisal F., Tomlins S., Lotan T., Schaeffer E.

1 Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America,
2 University of Michigan, Dept. of Urology and Pathology, Ann Arbor, United States of America,
3 Johns Hopkins University School of Medicine, Dept. of Urology
Pooled analysis of >1000 patients enrolled in two independent prospective validation studies show consistent performance of a urine exosome gene expression assay to rule-out benign and low-grade prostate cancer at initial biopsy

By: Noerholm M. ¹, McKiernan J. ², Donovan M.J. ³, Partin A. ⁴, Carter B. ⁴, Brown G. ⁵, Margolis E. ⁶, Torkler P. ¹, Skog J. ⁷, Shore N. ⁸, Andriole G. ⁹, Thompson I. ¹⁰, Carroll P. ¹¹

¹Exosome Diagnostics GmbH, Martinsried, Germany, ²Columbia University Medical Center, Dept. of Urology, New York, United States of America, ³Icahn School of Medicine at Mt. Sinai, Dept. of Pathology, New York, United States of America, ⁴Johns Hopkins Hospital, Dept. of Urology, Baltimore, United States of America, ⁵Delaware Valley Urology, Voorhees, United States of America, ⁶Urology Center of Englewood, Englewood, United States of America, ⁷Exosome Diagnostics, Waltham, United States of America, ⁸Atlantic Urology Clinics, Myrtle Beach, United States of America, ⁹Washington University, Dept. of Surgery, Saint Louis, United States of America, ¹⁰UT Health Science Center, San Antonio, United States of America, ¹¹University of California, Dept. of Urology, San Francisco, United States of America

Identification of clinically significant prostate cancer using a novel multiplexed urine biomarker panel

By: Niknafs Y. ¹, Tosoian J. ², Morgan T. ², Tomlins S. ¹, Chinnaiyan A.M. ¹

¹University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Urology, Ann Arbor, United States of America

Prostate cancer (PCa) incidence and severity in 823 hypogonadal men with and without testosterone therapy (TTh) in a controlled, observational registry study over up to 14 years

By: Haider A., Haider K.S.
Praxis Dr. Haider, Dept. of Urology, Bremerhaven, Germany

Low free testosterone is an independent risk factor for high grade prostate cancer

By: Towe M., Huynh L.M., El-Khatib F.M., Osman M., Yafi F., Ahlering T.
University of California, Irvine, Dept. of Urology, Orange, United States of America

International comparison in the Risk Calculator-based age-standardized incidence rate of prostate cancer between Japan and the Netherlands

By: Ito K. ¹, Oki R. ¹, Suzuki R. ², Fujizuka Y. ³, Arai S. ³, Miyazawa Y. ³, Sekine Y. ³, Shibata Y. ³, Suzuki K. ³, Kurosawa I. ¹, Roobol M.J. ⁴

¹Kurosawa Hospital, Institute for Preventive Medicine, Takasaki, Japan, ²Gunma University Hospital, Dept. of Urology, Maebashi, Japan, ³Gunma University Graduate School of Medicine, Dept. of Urology, Maebashi, Japan, ⁴Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands
### 109 Clinical significant prostate cancer diagnostic performance of LacdiNAc-prostate-specific antigen glycoisomer assay at initial prostate biopsy: Retrospective multi-institutional study


1Hirosaki University Graduate School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan, 2Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 3Konica Minolta Inc., Corporate R&D Headquarters, Hino, Japan, 4Tohoku University Graduate School of Medicine, Dept. of Urology, Sendai, Japan, 5McMaster University, Dept. of Surgery, Ontario, Canada, 6Gifu University Graduate School of Medicine, Dept. of Urology, Gifu, Japan, 7University of Queensland, Centre for Clinical Research (UQCCR), Herston, Australia

### 110 Detection of significant prostate cancer through exhaled-breath analysis with an electronic nose, Aeonose™


Maastricht University Medical Centre, Dept. of Urology, Maastricht, The Netherlands

### 111 The neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of response to abiraterone acetate: A retrospective analysis of the COU302 study

By: **Loubersac T.**, **Nguile-Makao M.**, **Pouliot F.**, **Fradet V.**, **Toren P.**

1CHU Nantes, Urology Unit, Nantes, France, 2Centre Hospitalier Universitaire (CHU) de Québec Research Centre, Urology Unit, Quebec City, Canada

### 112 Prognostic significance of serum γ-glutamyltransferase in patients with castration-resistant prostate cancer treated with enzalutamide


Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan

### 12:00 - 12:08 State-of-the-art lecture How to develop a clinically relevant biomarker

J.A. Schalken, Nijmegen (NL)